Remote monitoring and telemedicine: a match made in digital health heaven?
It’s tempting to think that IoT infrastructure and AI make remote disease monitoring straightforward. But even when this is technically feasible, healthcare system innovation is necessary to make the most of opportunities created by digital health.
Can we imagine a future of personalised medicine based on the analysis of lipids and carbohydrates?
DNA to RNA to protein – from this simple but powerful concept was born first biotechnology and then personalised medicine. But are we missing something? Can we imagine a future of personalised medicine based on the analysis of lipids and carbohydrates?
Design for adherence: a model for predicting and improving medication adherence
Medication adherence is often studied after a drug or delivery device has been developed, but what if we were able to predict levels of adherence for a particular drug delivery device during development?
Beyond pixel number: Where next for endoscopic imaging capabilities?
Relentless progress in imaging sensors driven by the smart phone camera revolution is beginning to transform the optical capabilities of endoscopes. Beyond pixel number, this also raises the prospect of challenger business models that offer altogether new imaging capabilities, or disposable endoscopes.
Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies
Bioprocess International Conference in Boston panel.
New dimensions in 3D bioprinting
Late stage failures in drug development are extremely costly for pharmaceutical companies and stifle innovation. Now non-traditional methods such as 3D bioprinting are being brought to bear on this challenge.
Navigating the market for “PoC” diagnostic systems
Several companies have developed, or are currently developing, products for the “point-of-care” molecular diagnostics market. In reality, the molecular diagnostics market is heterogeneous, and few applications are likely to arise truly at the point of care—indeed “point-of-clinic” would be a better description for this market.
Predicting failure rates in cell therapy manufacturing: is one in a million good enough?
Autologous cell therapy has had some remarkable clinical success, but to get to where it is today, industry has relied heavily on repurposed R&D equipment to manufacture individual batches of cell therapy.
Editing the genomes of superbugs to combat antibiotic resistance
Pathogenic bacteria that resist nearly all antibiotics are continuing to spread worldwide, the human population is getting sicker, and experts are scrambling to fix the problem. Innovative approaches that target bacterial genomes may be part of a much-needed solution to the growing crisis of antibiotic resistance.
The Future of Human Healthcare: Rise of the Netborgs
TTP welcomes guest author Frank F Craig PhD MBA of Sphere Fluidics Limited to the blog.